Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Centre Oscar Lambret
Medical University of South Carolina
Jinling Hospital, China
Thomas Jefferson University
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
MacroGenics
M.D. Anderson Cancer Center
Johns Hopkins University
Exelixis
Taiho Oncology, Inc.
University of Utah
Medical University of South Carolina
UNC Lineberger Comprehensive Cancer Center
Jinling Hospital, China
Gustave Roussy, Cancer Campus, Grand Paris
Yale University
NRG Oncology
University of California, San Francisco
Medical College of Wisconsin
Incyte Corporation
Dana-Farber Cancer Institute
Tempus AI
ImmuneSensor Therapeutics Inc.
National Cancer Institute (NCI)
Day One Biopharmaceuticals, Inc.
Merus B.V.
G1 Therapeutics, Inc.
University of Washington
Telix Pharmaceuticals (Innovations) Pty Limited
Brown University
University of Washington
AHS Cancer Control Alberta
Royal Marsden NHS Foundation Trust
University of California, San Francisco
Coherus Oncology, Inc.
Thomas Jefferson University
University of Chicago
European Association of Urology Research Foundation
Centre hospitalier de l'Université de Montréal (CHUM)
Elevation Oncology
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Incyte Corporation
Seagen Inc.
Emory University
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
University of California, San Diego